Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 540 results for "Tecfidera"

Tecfidera Continues to Be Key Revenue Driver for Biogen in 1Q16

Strong Product Portfolio Drove Biogen's 1Q16 Profit Margins ( Continued from Prior Part ) Tecfidera performance By the end of 1Q16, Biogen's (BIIB) leading multiple sclerosis (or MS) drug, Tecfidera, had treated about 190,000 multiple ... Yahoo! Finance UK and Ireland, 1 month ago
Biogen Witnessed Strong Growth in Net Profit Margins in 1Q16 Yahoo! Finance UK and Ireland, 2 weeks ago
Tysabri Reports Strong Patient Growth in 1Q16 Yahoo! Finance UK and Ireland, 1 month ago

8 images for Tecfidera

Motley Fool, 1 month ago
European Pharmaceutical Review, 1 month ago, 1 month ago
Nasdaq, 1 month ago
Nasdaq, 1 month ago
Nasdaq, 1 month ago
Nasdaq, 1 month ago, 1 month ago
European Pharmaceutical Review

TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness

-- More than Half of Newly Diagnosed MS Patients Taking TECFIDERA Remained Free of Relapse and Disability Progression Over Six Years -- -- New Analyses Show TECFIDERA Associated with Significantly Lower ARR Relative to Glatiramer Acetate, ...
 Bloomberg1 month ago Tecfidera demonstrates sustained efficacy in RRMS studies  European Pharmaceutical Review1 month ago TECFIDERA data confirm strong and sustained efficacy in newly diagnosed MS patients and real-world effectiveness  Medical News Today1 month ago Biogen Reports TECFIDERA Data Confirms Strong, Sustained Efficacy in Newly-Diagnosed MS Patients  Morningstar.com1 month ago

Biogen Q1 profits rise boosted by Tecfidera sales

Shares in Biogen (Nasdaq: BIIB) climbed to close up over 5% Thursday after the company reported 18% rise in first-quarter profit driven by sales ofmultiple-sclerosis drug Tecfidera. The biotech firm reported profit of $970.9 million, or $4.43 a ...
 Pharmafile1 month ago Biogen Profit Climbs On Higher Sales of Multiple-Sclerosis Drug  Nasdaq1 month ago Tecfidera sales growth fuels Biogen's rise in first-quarter revenue, profit  FirstWord Pharma1 month ago BIOGEN : Profit Climbs, Helped by Stronger Sales of Tecfidera  4 Traders1 month ago

MERCK KGAA : EMD Serono to Present Data Assessing Comparative Effectiveness of Rebif® interferon beta-1a vs. TECFIDERA® dimethyl fumurate at AAN Annual Meeting

By a News Reporter-Staff News Editor at Clinical Trials Week -- EMD Serono, the North America biopharmaceutical business of Merck KGaA, Darmstadt, Germany, announced that clinical and real-world data about Rebif(®) (interferon beta-1a), will be ...
 4 Traders1 month ago EMD Serono to Present Data Assessing Comparative Effectiveness of Rebif® interferon beta-1a vs. TECFIDERA® dimethyl fumurate at AAN Annual Meeting  Equities.com1 month ago
Investor's Business Daily

Gilead, Biogen Down On Patent Rulings; Ionis, Merck, Forward Rise

Ionis and Merck won their case on Gilead's sofosbuvir, while Biogen's Tecfidera patent will be reviewed. Big biotechs Gilead Sciences ( GILD ) and Biogen ( BIIB ) were both trading down Wednesday morning after receiving unfavorable patent news. ...
 Wall Street Select2 months ago Gilead Has Great Value Now; No Need For It To Make A Big Deal  Seeking Alpha1 week ago

February 2016 Tecfidera Label Change Adds Information About PML Risks

There seems to have been more Tecfidera progressive multifocal leukoencephalopathy (PML) cases reported in the past year or so. And it seems that lymphonpenia possibly induced by Tecfidera might have a role to play in those additional PML cases. ...
 DrugInjuryLaw.com2 weeks ago A Tecfidera Label Change Modifying Warnings About Progressive Multifocal Leukoencephalopathy (PML) Was Done In February 2016 With Little Notice  Drug Injury Watch2 weeks ago Tecfidera (dimethyl fumarate)  Drugs.com2 months ago

Biogen's controversial Tecfidera ad is about to meet its end

Biogen's DTC ad for multiple sclerosis pill Tecfidera has garnered its fair share of criticism from patients who say it's unrealistic. But that didn't stop the TV commercial from getting the job done, the company says--and now that it has, it's on ...
 FiercePharma3 weeks ago Biogen's 'active woman' Tecfidera ad will go off air soon  BioPharma Dive1 month ago

TECFIDERA® data highlights benefit of early treatment in relapsing-remitting multiple sclerosis

Biogen present new TECFIDERA (dimethyl fumarate) research at the 68th annual meeting of the American Academy of Neurology (AAN) in Vancouver, Canada. The data presented supports the value of dimethyl fumarate in the treatment of patients with ...
 Hospital Pharmacy Europe1 month ago
Proactive Investors USA

Biogen profit beats estimates as costs fall, Tecfidera sales rise

* Tecfidera sales rise 15 pct to $946 mln * Total costs down 6.2 pct * 1st-qtr profit $4.79/shr vs est. $4.47 (Adds details, analysts' comment; updates shares) By Amrutha Penumudi April 21 (Reuters) - Biogen Inc reported a better-than-expected ...
 Sharenet1 month ago Biogen tops Wall Street estimates for quarter  Proactive Investors USA1 month ago Cost cutting helps Biogen top Wall Street estimates for quarter  Sharenet1 month ago UPDATE 3-Cost cutting helps Biogen top Wall Street estimates for quarter  Reuters UK1 month ago

Fingolimod Easier to Swallow Than Dimethyl Fumarate?

Fingolimod (Gilenya, Novartis) was better tolerated than dimethyl fumarate (Tecfidera, Biogen) in a 2-year comparison of the oral multiple sclerosis
 RxList1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Tecfidera
Get updated on latest news & your favorite topics right in your inbox!
More     Less